A Phase 3 interventional study of MT-6548 in Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease, sponsored by Tanabe Pharma Corporation. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Treatment
To evaluate the efficacy and safety of MT-6548 in peritoneal dialysis subjects with anemia associated with chronic kidney disease
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
This study's enrollment of 42 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Browse Anemia studies →Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ophthalmic examinations during the screening period correspond to either of the following criteria;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MT-6548
Oral tablet
Also known as: vadadustat, AKB-6548
Mean Hb Level of Week 20 and Week 24
Time frame: Up to Week 24
Hb Level at Each Assessment Time Point
Time frame: Up to Week 24
Percentage of Subjects With Hb Level at Each Assessment Time Point Within the Target Range During the Treatment Period
Time frame: Up to Week 24
Time to Reach the Target Hb Range in Correction Group Only
Time frame: Up to Week 24
Rate of Increase in Hb Level in Correction Group Only
Time frame: Up to Week 6
| Milestone | MT-6548 |
|---|---|
| Started | 42 |
| Correction group | 2 |
| Conversion group | 40 |
| Completed | 36 |
| Not completed | 6 |
| Withdrew: Adverse event | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Difficult to control hb | 2 |
| g/dL | MT-6548 |
|---|---|
| Mean Hb Level of Week 20 and Week 24 | 11.35 (10.99 to 11.70) |
| g/dL | MT-6548 |
|---|---|
| Baseline | 10.90 (10.56 to 11.25) |
| Week 2 | 10.96 (10.54 to 11.38) |
| Week 4 | 10.74 (10.31 to 11.17) |
| Week 6 | 10.61 (10.09 to 11.13) |
| Week 8 | 10.87 (10.41 to 11.33) |
| Week 10 | 10.89 (10.45 to 11.32) |
| Week 12 | 11.10 (10.67 to 11.53) |
| Week 16 | 11.58 (11.12 to 12.04) |
| Week 20 | 11.68 (11.24 to 12.13) |
| Week 24 | 11.39 (11.00 to 11.79) |
| Week 24 (LOCF) | 11.01 (10.54 to 11.47) |
| percentage of subjects | MT-6548 |
|---|---|
| Baseline | 57.1 |
| Week 2 | 60.0 |
| Week 4 | 41.5 |
| Week 6 | 35.9 |
| Week 8 | 47.4 |
| Week 10 | 44.7 |
| Week 12 | 44.7 |
| Week 16 | 32.4 |
| Week 20 | 66.7 |
| Week 24 | 65.7 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MT-6548 | 1/42 (2.4%) | 12/42 (28.6%) | 21/42 (50%) |
| Event | MT-6548 |
|---|---|
| PeritonitisInfections and infestations | 3/42 |
| Peripheral arterial occlusive diseaseVascular disorders | 2/42 |
| AnaemiaBlood and lymphatic system disorders | 1/42 |
| Cardiac failure chronicCardiac disorders | 1/42 |
| Myocardial ischaemiaCardiac disorders | 1/42 |
| Gastric polypsGastrointestinal disorders | 1/42 |
| Inguinal herniaGastrointestinal disorders | 1/42 |
| Catheter site infectionInfections and infestations | 1/42 |
| SepsisInfections and infestations | 1/42 |
| Peritoneal dialysis complicationInjury, poisoning and procedural complications | 1/42 |
| Event | MT-6548 |
|---|---|
| Catheter site infectionInfections and infestations | 9/42 |
| DiarrhoeaGastrointestinal disorders | 8/42 |
| NasopharyngitisInfections and infestations | 6/42 |
| VomitingGastrointestinal disorders | 4/42 |
| Abdominal pain upperGastrointestinal disorders | 3/42 |
| NauseaGastrointestinal disorders | 3/42 |
| Decreased appetiteMetabolism and nutrition disorders | 3/42 |
| Age, Categorical(Participants) | MT-6548 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 19 |
| >=65 years | 23 |
| Sex: Female, Male(Participants) | MT-6548 |
|---|---|
| Female | 12 |
| Male | 30 |
| Race/Ethnicity, Customized(Participants) | MT-6548 |
|---|---|
| Asian (Japanese) | 42 |
| Asian (Other) | 0 |
| Other | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Nov 2018, 10 months.
Results were first posted in Jul 2021, 2 years 7 months after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 10 months is below that.
Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat